SUMMIT THERAPEUTICS INC (SMMT) Fundamental Analysis & Valuation

NASDAQ:SMMT • US86627T1088

Current stock price

25.15 USD
+0.73 (+2.99%)
At close:
25.19 USD
+0.04 (+0.16%)
After Hours:

This SMMT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SMMT Profitability Analysis

1.1 Basic Checks

  • SMMT had negative earnings in the past year.
  • In the past year SMMT has reported a negative cash flow from operations.
  • In the past 5 years SMMT always reported negative net income.
  • In the past 5 years SMMT always reported negative operating cash flow.
SMMT Yearly Net Income VS EBIT VS OCF VS FCFSMMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • SMMT's Return On Assets of -230.24% is on the low side compared to the rest of the industry. SMMT is outperformed by 90.50% of its industry peers.
  • SMMT has a Return On Equity of -287.57%. This is in the lower half of the industry: SMMT underperforms 73.64% of its industry peers.
Industry RankSector Rank
ROA -230.24%
ROE -287.57%
ROIC N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
SMMT Yearly ROA, ROE, ROICSMMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SMMT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMMT Yearly Profit, Operating, Gross MarginsSMMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SMMT Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, SMMT has more shares outstanding
  • SMMT has more shares outstanding than it did 5 years ago.
  • SMMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SMMT Yearly Shares OutstandingSMMT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
SMMT Yearly Total Debt VS Total AssetsSMMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • SMMT has an Altman-Z score of 161.09. This indicates that SMMT is financially healthy and has little risk of bankruptcy at the moment.
  • SMMT has a better Altman-Z score (161.09) than 99.03% of its industry peers.
  • There is no outstanding debt for SMMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 161.09
ROIC/WACCN/A
WACCN/A
SMMT Yearly LT Debt VS Equity VS FCFSMMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • SMMT has a Current Ratio of 5.13. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SMMT (5.13) is comparable to the rest of the industry.
  • SMMT has a Quick Ratio of 5.13. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
  • SMMT has a Quick ratio of 5.13. This is comparable to the rest of the industry: SMMT outperforms 56.78% of its industry peers.
Industry RankSector Rank
Current Ratio 5.13
Quick Ratio 5.13
SMMT Yearly Current Assets VS Current LiabilitesSMMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SMMT Growth Analysis

3.1 Past

  • The earnings per share for SMMT have decreased strongly by -161.29% in the last year.
EPS 1Y (TTM)-161.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 36.80% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-32.62%
EPS Next 2Y-16.6%
EPS Next 3Y11.69%
EPS Next 5Y36.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SMMT Yearly Revenue VS EstimatesSMMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B 10B
SMMT Yearly EPS VS EstimatesSMMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. SMMT Valuation Analysis

4.1 Price/Earnings Ratio

  • SMMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMMT Price Earnings VS Forward Price EarningsSMMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMMT Per share dataSMMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.6%
EPS Next 3Y11.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SMMT Dividend Analysis

5.1 Amount

  • SMMT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SMMT Fundamentals: All Metrics, Ratios and Statistics

SUMMIT THERAPEUTICS INC

NASDAQ:SMMT (4/17/2026, 8:00:02 PM)

After market: 25.19 +0.04 (+0.16%)

25.15

+0.73 (+2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-29
Earnings (Next)05-07
Inst Owners15.5%
Inst Owner Change-0.02%
Ins Owners82.62%
Ins Owner Change2.45%
Market Cap19.50B
Revenue(TTM)N/A
Net Income(TTM)-746.08M
Analysts77.39
Price Target31.42 (24.93%)
Short Float %25.64%
Short Ratio14.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.73%
Min EPS beat(2)-24.49%
Max EPS beat(2)3.04%
EPS beat(4)2
Avg EPS beat(4)-8.83%
Min EPS beat(4)-24.49%
Max EPS beat(4)3.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.15%
PT rev (3m)-8.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 75.16
P/tB 75.76
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -230.24%
ROE -287.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 475%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.13
Quick Ratio 5.13
Altman-Z 161.09
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)90.01%
Cap/Depr(5y)64.02%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-161.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
EPS Next Y-32.62%
EPS Next 2Y-16.6%
EPS Next 3Y11.69%
EPS Next 5Y36.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-123.2%
EBIT Next 3Y-57.65%
EBIT Next 5Y-25.24%
FCF growth 1Y-352.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-352.1%
OCF growth 3YN/A
OCF growth 5YN/A

SUMMIT THERAPEUTICS INC / SMMT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUMMIT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SMMT.


Can you provide the valuation status for SUMMIT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to SUMMIT THERAPEUTICS INC (SMMT). This can be considered as Overvalued.


How profitable is SUMMIT THERAPEUTICS INC (SMMT) stock?

SUMMIT THERAPEUTICS INC (SMMT) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SUMMIT THERAPEUTICS INC?

The Earnings per Share (EPS) of SUMMIT THERAPEUTICS INC (SMMT) is expected to decline by -32.62% in the next year.